First Tracks Biotherapeutics Stock Price, News & Analysis
Company Description
First Tracks Biotherapeutics (NASDAQ: TRAXV) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $782.2M, ranking #3,117 among all listed U.S. companies by market cap.
TRAXV stock has gained 18.5% over the past year.
This page provides a comprehensive overview of TRAXV stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
First Tracks Biotherapeutics (TRAXV) stock. Over the past 12 months, the stock has gained 18.5%. At a market capitalization of $782.2M, TRAXV is classified as a small-cap stock with approximately 34.7M shares outstanding.
TRAXV Rankings
Latest News
SEC Filings
First Tracks Biotherapeutics has filed 5 recent SEC filings, including 2 Form 3, 2 Form 4, 1 Form SCHEDULE 13G. The most recent filing was submitted on April 23, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all TRAXV SEC filings →
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
TRAXV Company Profile & Sector Positioning
First Tracks Biotherapeutics (TRAXV) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ. In monthly performance, the stock ranks #619 among all tracked companies.